A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Two Eloralintide Solutions in Healthy Participants
Eli Lilly and Company
Summary
The main purpose of this study is to learn about safety, tolerability and how well the body processes two different eloralintide solutions. Participation in this study will last about 13 weeks, including screening, inpatient treatment, and follow-up.
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation * Have a body mass index (BMI) within the range of 20.0 to 32.0 kilogram per square meter (kg/m2), inclusive Exclusion Criteria: * Have known allergies to related compounds of eloralintide, or any of the components of the formulations * Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data * Have been diagnos…
Interventions
- DrugEloralintide
Administered SC.
Locations (2)
- Fortrea Clinical Research UnitDaytona Beach, Florida
- Fortrea Clinical Research UnitDallas, Texas